BioNTech lays out plans for $251M IPO; Trio teams up to form joint lab to research chronic lung diseases
→ Earlier this month, German cancer drug developer BioNTech laid out plans for a $100 million public listing in the US, two months after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
